Precigen, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
PGEN
Precigen, INCPrecigen Inc. announced its first-quarter 2026 financial results, showcasing a significant increase in product revenues driven by the commercial launch of Papzimeos.
NASDAQ
PGEN
Precigen, INCPrecigen reports significant Q3 2025 financial shifts, driven by the FDA approval of Papzimeos and a substantial increase in net loss due to warrant reclassification and preferred stock conversion.
NASDAQ
PGEN
Precigen, INCPrecigen reported a reduced net loss for the first half of 2025, driven by strategic pipeline prioritization and cost reductions, but faces substantial doubt about its ability to continue as a going concern without additional funding.
NASDAQ
PGEN
Precigen, INC10-Q: Precigen Reports Q1 2025 Results, Faces Going Concern Uncertainty Despite PRGN-2012 Priority Review
Precigen's Q1 2025 results reveal a net loss of $54.15 million and raise substantial doubt about its ability to continue as a going concern, despite FDA priority review for PRGN-2012.
NASDAQ
PGEN
Precigen, INCPrecigen, Inc. announced its third quarter 2024 results, highlighting a strategic shift towards its PRGN-2012 program and a reduction in workforce.
NASDAQ
PGEN
Precigen, INCPrecigen announced its Q2 2024 financial results and a strategic shift to prioritize the development of PRGN-2012, including a reduction in workforce and the shutdown of ActoBio operations.
NASDAQ
PGEN
Precigen, INCPrecigen's first quarter 2024 results show a net loss of $23.7 million and highlight substantial doubt about the company's ability to continue as a going concern.